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Abstract
Background: Brain mitochondrial dysfunction is implicated in the pathophysiology of mood 
disorders. Brain cytochrome-c-oxidase (COX) activity is associated with mitochondrial function. 
Near-infrared spectroscopy (NIRS) non-invasively measures oxidized COX (oxCOX) and tissue 
oxygenation index (TOI) reflecting cerebral blood flow and oxygenation.
Methods: oxCOX and TOI were assessed in prefrontal cortex (Fp1/2, Brodmann area 10) in 
patients in a major depressive episode (N=13) with major depressive disorder (MDD; N=7) and 
bipolar disorder (BD; N=6) compared to controls (N = 10). One MDD patient and all BD patients 
were taking medications. Computational modelling estimated oxCOX and TOI related indices of 
mitochondrial function and cerebral blood flow, respectively.
Results: oxCOX was lower in patients than controls (p=0.014) correlating inversely with 
depression severity (r=−0.72, p = 0.006), driven primarily by lower oxCOX in BD compared with 
controls. Computationally modelled mitochondrial parameters of the electron transport chain, such 
as the nicotinamide adenine dinucleotide ratio (NAD+/NADH p=0.001) and the proton leak rate 
across the inner mitochondrial membrane (klk2 p=0.008), were also lower in patients and 
correlated inversely with depression severity. No such effects were found for TOI.
Conclusions: In this pilot study, oxCOX and related mitochondrial parameters assessed by 
NIRS indicate an abnormal cerebral metabolic state in mood disorders proportional to depression 
Corresponding author: Lisa Holper, Department of Psychiatry, Psychotherapy, and Psychosomatics, Hospital of Psychiatry, University 
of Zurich, Lenggstrasse 31, CH-8032 Zurich, Switzerland, Phone: +41 44 389 15 70, holper@ini.phys.ethz.ch. 
Conflict of Interest
Dr. Mann received royalties for commercial use of the C-SSRS from the Research Foundation of Mental Hygiene. Dr. Lan received 
salary support from an Independent Medical Education Grant from Sunovion Pharmaceuticals. The other authors report no conflict of 
interest.
Data availability statement
Authors provide the data if requested.
HHS Public Access
Author manuscript
Depress Anxiety. Author manuscript; available in PMC 2020 August 01.
Published in final edited form as:













severity, potentially providing a biomarker of antidepressant effect. Since the effect was driven by 
the medicated BD group, findings need to be evaluated in a larger, medication-free population.
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1 Introduction
More than 300 million people suffer from mood disorders globally. Mood disorders are 
projected to be the leading cause of disability-adjusted life years lost by 2030 (NIH 2018). 
Heterogeneity of depression is indicated by pleomorphism of its symptom and the 
observations that up to 60% of patients do not respond adequately to medications (Nemeroff 
2007; Wiles, Thomas, and Abel A 2014). Multiple neurobiological and psychosocial factors 
are thought to contribute to mood disorders, yet biomarkers that can guide treatment 
selection have proven limited (Strawbridge, Young, and Cleare 2017).
Mitochondrial dysfunction has been proposed as a contributing factor to the 
pathophysiology of mood disorders (Bansal and Kuhad 2016; Kato 2017). Mitochondria are 
intracellular organelles that produce adenosine triphosphate (ATP), the main source of 
cellular energy (Picard, Wallace, and Burelle 2016). Impaired mitochondrial function results 
in decreased ATP production, and more apoptosis and oxidative stress (Fišar and Hroudová 
2010; Hroudová and Fišar 2011). ATP deficiency and the resulting alterations in energy 
metabolism may explain some features of mood disorders, e.g., physiological (sleep 
disturbances, fatigue), psychological (depressed mood, lack of motivation) and 
neurocognitive (impaired concentration and memory) abnormalities (E. Streck et al. 2014; 
Karabatsiakis et al. 2014). Primary mitochondrial disorders are associated with higher rates 
of depression (Anglin et al. 2012).
Prior to generation of ATP, oxidative phosphorylation diverts electrons extracted from 
nutrients into a transmembrane proton gradient, a process mediated by the electron transport 
chain (ETC) (Li et al. 2006). Cytochrome-c-oxidase (COX) is the final enzyme in the ETC, 
which is responsible for the maintenance of the transmembrane proton gradient that is used 
for ATP synthesis (Wikstrom 1977). Based on its rate-limiting role in this oxidative process 
(Arnold 2012), COX is considered a key marker of mitochondrial function (Srinivasan and 
Avadhani 2012).
Lower COX levels have been previously reported in major depressive disorder (MDD) and 
bipolar disorder (BD) based on peripheral blood measures, muscle biopsies and postmortem 
brain samples (for review see (L. Holper, Ben-Shachar, and Mann 2018)). In MDD, lower 
COX enzyme activity has been reported in peripheral platelets (Ben-Shachar et al. 1999) and 
muscle (Gardner et al. 2003, 2008) but greater COX mRNA expression has been found in 
serotonergic neurons of postmortem nucleus raphe in depressed suicide decedents (Sanchez-
Bahillo et al. 2008). In BD, low COX enzyme activity, mRNA and protein expression have 
been reported in peripheral blood (Ben-Shachar et al. 1999; de Sousa et al. 2015; Naydenov 
AV et al. 2007; Washizuka et al. 2005; Beech et al. 2010), postmortem hippocampus (Altar 
et al. 2005; Konradi C et al. 2004) and postmortem frontal cortex (Iwamoto, Bundo, and 
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Kato 2005; H. K. Kim et al. 2016; X. Sun et al. 2006). Further, there is evidence of abnormal 
mitochondrial function in vivo in the brain using neuroimaging methods. Specifically, 18F-
fluorodeoxyglucose positron emission tomography (18F-FDG-PET) reveals metabolic 
changes in glucose utilization primarily in MDD that generally involves lower glucose 
uptake in dorsolateral prefrontal cortical and increased uptake in subcortical and ventral 
prefrontal cortex (De Crescenzo et al. 2017; Su et al. 2014; Schöll, Damián, and Engler 
2014). Phosphorus (31)P magnetic resonance spectroscopy (MRS) has been used to assess 
decreased phosphocreatine as an indicator of mitochondrial oxidative phosphorylation, for 
example in frontal lobe, primarily in BD (for reviews see (Kato 2017; Quiroz et al. 2008; 
Clay, Sillivan, and Konradi 2011; Stork and Renshaw 2005; Moretti, Gorini, and Villa 
2003)). However, while these techniques can assess some aspects of mitochondrial 
functions, they cannot measure COX activity directly.
To investigate COX activity in the present study, we used near-infrared spectroscopy (NIRS), 
an optical neuroimaging method. Compared to PET and MRS, NIRS is non-invasive, 
relatively low-cost, does not involve radiation, and can be applied in a physically minimally 
demanding setting (Obrig and Villringer 2003; Ferrari and Quaresima 2012; Wolf, Ferrari, 
and Quaresima 2007; Ferrari, Mottola, and Quaresima 2004). In our previous work, we 
showed that the COX signal has adequate test-retest reliability (Lisa Holper and Mann 
2018). Consequently, NIRS permits highly feasible assessment of brain COX as a marker of 
mitochondrial function.
NIRS measures the oxidative state of COX’s chromophore (its binuclear copper CuA center), 
termed oxCOX signal, as well as hemodynamic signals in terms of oxygenated (HbO2) and 
deoxygenated (HHb) hemoglobin. Compared to the hemodynamic signals routinely assessed 
using NIRS (Ferrari and Quaresima 2012), the oxCOX signal has hitherto not been routinely 
assessed. While HbO2 and HHb provide information on blood flow and oxygenation, 
oxCOX is considered a key indicator of cellular oxygen metabolism (Ilias Tachtsidis et al. 
2009; Highton et al. 2014; Kolyva et al. 2013; Ghosh et al. 2013). The concentration of 
oxCOX is approximately 10% that of hemoglobin, which makes it harder to detect. On the 
other hand, oxCOX is a stable (Bale, Elwell, and Tachtsidis 2016) and reliable signal (Lisa 
Holper and Mann 2018) with high brain specificity (de Roever et al. 2016). Thus, alterations 
in oxCOX indicate a change in mitochondrial metabolic balance (Bainbridge et al. 2014).
Previously, it has been shown that the oxCOX signal is a potential marker of mitochondrial 
function (Caldwell, Hapuarachchi, et al. 2015). Specifically, lower oxCOX activity, as 
hypothesized in major depressive episodes (MDE), can be related to reductions in 
mitochondrial parameters derived from computational modelling (Caldwell, Hapuarachchi, 
et al. 2015). In the present pilot study, we hypothesized that the oxCOX signal would be 
lower in MDE compared with control subjects.
2 Methods and materials
2.1 Study population
Patients with either DSM-IV MDD or BD were recruited at the New York State Psychiatric 
Institute (NYSPI)/Columbia University Medical Center. Patients were compared with 
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physically and psychiatrically healthy controls (HC). All participants were assessed 
diagnostically using the Structured Clinical Interview for Axis I disorders (SCID-I/P) (First 
et al. 2002), the 24-item Hamilton Depression Rating Scale (HDRS) (Hamilton 1960) and 
the Young Mania Rating Scale (YMRS) (Young et al. 1978). Exclusion criteria for all 
participants included any uncontrolled medical condition, history of head trauma, any other 
major psychiatric disorder such as schizophrenia, schizoaffective disorder, current psychotic 
depression, substance abuse within the previous three months or substance dependence 
within the previous six months, a history of intolerable side effects from both citalopram and 
fluoxetine, a first-degree family history of schizophrenia, current serious suicidal ideation or 
behavior, pregnancy or currently lactating women. The Institutional Review Board of 
NYSPI approved the study protocol, and all participants gave written informed consent. All 
patients were taking part in other study protocols at NYSPI, explaining the variation in 
medication regimens, and why the MDD group was older than the other groups.
2.2 Respiratory challenges
Quantification of the oxCOX signal demands significant changes in arterial oxygen 
saturation to be reliably detected in the cortex. We therefore chose two respiratory 
challenges to systemically manipulate cerebral oxygenation via hypo- and hypercapnia, i.e., 
reduced and increased carbon dioxide in the blood, with the order of the challenges 
counterbalanced between participants (L. Holper, Scholkmann, and Seifritz 2015; Kolyva et 
al. 2014). Hypocapnia was induced by hyperventilation consisting of five repetitions of 
alternate periods of rapidly breathing in and out with constant respiratory volume (20 
seconds) and normal breathing (40 seconds). Hypercapnia was induced by breath-holding 
consisting of five repetitions of alternate periods of breath holding (20 seconds) and normal 
breathing (40 seconds). Prior to recording, participants were trained to perform the 
inspirational breath-holding a volume of air, similar to a normal breath cycle, in order to 
avoid inhaling larger volumes of air than that of a normal breath cycle. Before and after each 
challenge, resting-states of five minutes of data were collected, during which participants 
were asked to sit still in order to allow the hemodynamic cortical system to normalize. The 
resting-state periods were not included in the data analysis.
2.3 NIRS instrumentation
A NIRO 300 instrument (Hamamatsu Photonics) was used to measure the oxCOX, HbO2 
and HHb signals based in four discrete wavelengths (775, 810, 850, and 910 nm) (Ilias 
Tachtsidis et al. 2009, 2004; I Tachtsidis et al. 2007). Although, more recent broadband 
NIRS systems may obtain a more robust oxCOX signal (Bainbridge et al. 2014; Bale et al. 
2014; Arifler et al. 2015), we have reported adequate signal detection and test-retest 
reliability with NIRO 300 (Lisa Holper and Mann 2018). The NIRO 300 measures 
concentration changes of oxCOX, HbO2 and HHb based on conventional differential 
spectroscopy with the use of the modified Beer-Lambert law (Patterson, Chance, and Wilson 
1989; Delpy et al. 1988a). In addition, the system provides the tissue oxygenation index 
(TOI) based on the principle of spatially resolved reflectance spectroscopy (Delpy et al. 
1988b; Matcher et al. 1995), which is in essence the proportion of HbO2 relative to total 
hemoglobin (HbO2 + HHb) concentration (Susumu Suzuki et al. 1999; Ilias Tachtsidis et al. 
2008). The system uses four light sources (pulsed laser diodes) and three detectors 
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(photodiodes) held in a light-proof holder, set at a distance of 4.5 cm, fixed in a rubber probe 
to allow for direct skin contact. Two channels were positioned to cover parts of the 
prefrontal cortex (i.e., Fp1/2, Brodmann area 10). Data were detrended, zero-meaned, and 
bandpass-filtered in the range 0.005 – 0.3 Hz, using a 5th order Butterworth filter, to remove 
physiological noise, based on functions of the HOMER2 processing package (Huppert et al. 
2009). Peripheral physiological measures were estimated using a capnometer (LifeSense 
LS1–9R, Nonin Medical) by means of the arterial tissue oxygen saturation (SpO2) and the 
partial end-tidal carbon dioxide (PetCO2) of the exhaled air. Participants wore a nasal 
cannula through which tidal gases were sampled at 1 Hz.
2.4 Computational modelling
The computational procedures using the BS model outlined below regarding sensitivity 
analysis, model fit and model parameters are described in detail in previous work (Caldwell, 
Hapuarachchi, et al. 2015). The modelling of the oxCOX signal was our a priori primary 
metabolic signal of interest, because it provides important information about mitochondrial 
metabolic state related to reduced COX activity (Caldwell, Hapuarachchi, et al. 2015). The 
modelling of the TOI signal was our a priori secondary hemodynamic signal of interest 
(Caldwell, Hapuarachchi, et al. 2015). All modelling was performed separately for hypo-and 
hypercapnia, but results are presented averaged across both conditions, since no significant 
differences were found, as expected.
2.4.1 BS model—The BS model, described elsewhere (Caldwell, Hapuarachchi, et al. 
2015), models metabolism and cerebral blood flow in the human adult brain. Simulations 
were carried out using the Brain/Circulation Model Developer (Banaji et al. 2008) 
implemented in Python (Python Software Foundation). The model was applied with the 
following variables: 1) Input signals. The two model inputs were the experimentally 
measured PetCO2 and SpO2. 2) Output signals. The two model outputs were oxCOX and 
TOI. 3) Model parameters. Based on the input signals, the model simulates the behavior of 
the output signal based on a large parameter space (N = 139) reflecting cerebral metabolism. 
Simulations were run individually for each patient and control participant.
2.4.2 Sensitivity analysis and optimization—The 20 most influential model 
parameters for the oxCOX and TOI signals (Table 2) were selected for an exploratory 
sensitivity analysis using the extended Fourier Amplitude Sensitivity Test (eFAST) (Cukier 
et al. 1973; Schaibly and Shuler 1973). eFAST calculates the unique contribution of each 
model parameter in determining the model output based on variance decomposition, i.e., the 
first-order sensitivity index (S1) of a given parameter i, and a summed sensitivity index of 
the entire complementary set of parameters (all parameters except i), i.e., the total-order 
sensitivity indices (ST). The larger the S1, the more influential a parameter is on the output, 
while larger ST indicates a greater degree of interaction of a parameter i with other 
parameters.
Optimization of all 20 parameters was carried out using a Global Problem (GLP) solver 
(solver: de, maximum iterations 1000) to minimize the difference (Euclidean distance) 
between the measured and modelled signals on which the corresponding parameters were 
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influential. Parameters for each patient and control participant were optimized at once, in 
order to reduce the dimensionality of the optimizations (Caldwell, Moroz, et al. 2015). The 
initial model values (before optimization) and their ranges used for optimization are given in 
Table 2.
2.4.3 Statistical analysis—Statistical analysis was carried out using Matlab 
(Mathworks, Verision 2017b).
Preconditions for parametric testing, such as normality using the Lilliefors test and 
homogeneity of variance using O’Brien’s modification of Levene’s test, were checked for 
both oxCOX and TOI signals and their related parameter space.
Changes in the absolute block-averaged oxCOX and TOI signals were computed from 
baseline, i.e., time-locked two seconds before onset of hypo-/hypercapnia, to challenge, i.e., 
time-locked two seconds after offset of hypo-and hypercapnia.
Changes in the model parameters were expressed as percentage change (%) of the optimized 
values (after optimization) for each patient and control relative to the initial model values 
(before optimization).
Percentage Change % =
Optimized Value − Initial Value
Initial Value
*100 (1)
Linear mixed-effect regression was used to statistically assess the effect of patient versus 
control group (fixed effects) on the signal changes and corresponding optimized model 
parameters (responses), while controlling for age, PaCO2 and SaO2 (random effects) to 
account for normal aging and systemic effects; note that repeating the ANOVA without 
controlling for those covariates did not change results. ANOVA with Bonferroni correction 
was applied to account for multiple comparisons.
Spearman correlation coefficients were calculated to assess the relation of the signal changes 




Demographics of patients and controls are listed in Table 1. Higher HDRS scores (main 
effect F2 = 26.43, p < 0.0001) were seen in MDD (22.6 ± 11.6) and BD (23.5 ± 3.6) patients 
compared to controls (2.3 ± 2.2). In the MDD group, 6/7 of patients had late-life depression 
(LLD) and were thus older (64.4 ± 17.2) than the control (32.3 ± 10.06) and BD groups 
(40.8 ± 12.4) (main effect F2 = 16.57, p < 0.0001; post-hoc MDD vs. HC p < 0.0001; BD vs. 
HC p = 0.199, MDD vs. BD p = 0.007). Medication status also differed between groups. 
While 6/7 MDD subjects were medication-free, one MDD patient had started taking 
citalopram (20 mg/d) less than two weeks before scanning. All BD patients were on a 
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consistent dose of a mood stabilizer at scanning (1 × lithium 1350mg/d, 4 × valproic acid 
750–1000mg/d, 1 × lamotrigine 250mg/d) and 5/6 had started fluoxetine (20mg/d) less than 
two weeks prior to scanning (range 1 – 13 days).
3.2 Preconditions for parametric testing
The preconditions for parametric testing were fulfilled for both oxCOX and TOI signals and 
their related parameter space (not reported), including normality as assessed using the 
Lilliefors test (oxCOX signal: BD k-stats = 0.25, p = 0.287; MDD k-stats = 0.40, p = 0.001; 
HC k-stats = 0.17, p = 0.500; TOI signal: BD k-stats = 0.22, p = 0.468; MDD k-stats = 0.30, 
p = 0.168; HC k-stats = 0.22, p = 0.195) and homogeneity of variance between groups as 
assessed using O’Brien’s modification of Levene’s test (oxCOX signal F = 1.62, p = 0.222; 
TOI signal F = 0.04, p = 0.961).
3.3 Sensitivity analysis and optimization
In line with previous work (Caldwell, Hapuarachchi, et al. 2015), only a small part of the 
optimized model parameter space dominated the influence on the oxCOX and TOI signals, 
which space we selected for optimization. All parameters optimized reflected aspects of 
mitochondrial function and blood flow. The names and definitions of the parameters as well 
as the order of their sensitivity to the corresponding signals are given in Table 2.
3.4 Signal changes in oxCOX and TOI
Results revealed typical patterns of response to the respiratory challenges with hypocapnia 
producing a decrease in oxCOX and TOI and hypercapnia producing an increase in oxCOX 
and TOI (Bale, Elwell, and Tachtsidis 2016). The absolute block-averaged signal changes 
across both challenges revealed smaller oxCOX responses in the MDE groups (ANOVA 
main effect MDE vs. HC F2,20 = 7.22, p = 0.014), indicating less efficient COX function 
compared to controls (Figure 1, Top). This effect correlated strongly with depression 
severity across the MDE groups (Spearman, r = −0.72, p = 0.006) (Figure 2). By contrast, 
the hemodynamic signal TOI revealed no significant differences between groups (MDE vs. 
HC F2,20 = 0.50, p = 0.487) and no correlation with depression severity (Table 3).
Secondary ANOVA analyses assessing the effects of medication or age of the participants 
revealed no significant effects on either oxCOX or TOI (Table 3). Although the study was 
not powered to detect differences between MDD and BD groups, secondary analysis found 
no significant difference in oxCOX or TOI between MDD and BD groups. Nevertheless, the 
reduction in oxCOX in MDE groups compared to controls was driven primarily by lower 
oxCOX in the BD group, (Table 3).
3.5 Optimized model parameters for oxCOX and TOI
To provide a realistic picture of the differences in the parameters between patients and 
controls, the optimized values were expressed as percentage changes (%) relative to the 
initial value (Figure 1, Bottom). Statistical assessment using linear mixed-effect regression 
revealed that four model parameters optimized for the oxCOX signal were sensitive to the 
effects of depression. In particular, the parameters CuA,o,n (ANOVA main effect MDE vs. 
HC F2,20 = 9.86, p = 0.005), klk2 (F2,20 = 8.72, p = 0.007), NADn/NADHn (F2,20 = 14.18, p 
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= 0.001), and ck1 (F2,20 = 5.09, p = 0.035) decreased in the MDE groups, whereas ϕ (F2,20 = 
6.03, p = 0.023) increased in the MDE groups compared to controls, all primarily accounted 
for by the differences between BD and controls (Table 3). There were no significant 
differences detected between MDD versus BD. A separate ANOVA assessing medication 
effects revealed modest significant effects indicating decreasing NADn/NADHn (F2,20 = 
3.68, p = 0.044) and increasing ϕ (F2,20 = 3.74, p = 0.041) with medication, however without 
significant differences post-hoc comparisons, which again were not powered adequately 
given the small number of cases (Table 3).
Some parameters also showed a moderate correlation with depression severity after 
adjusting for age (Figure 2). In particular, klk2 (r = −0.63, p = 0.022) and COXtis (r = −0.58, 
p = 0.039) were inversely correlated with increasing depression severity indicating lower 
oxidative properties with higher symptom severity (Table 3).
Only one of the parameters optimized for the TOI signal, Kσ, showed a difference between 
MDE and controls (main effect MDE vs. HC F2,20 = 5.71, p = 0.026) but without correlation 
with depression severity. None of the other parameters optimized for TOI showed group 
differences (all p > 0.05) (Figure 1) or correlations with HDRS score (all p > 0.05) (Figure 
2, Table 3). ANOVA assessing medication effects revealed no significant effects on TOI 
parameters (Table 3).
3.6 Power analysis
Due to limitations of sample size, we performed a post-hoc power analysis using the pwr 
package (Champely 2018) in R (R Development Core Team 2008). Given the observed 
mean COX differences between HC and MDE groups of d = 1.13 (between HC and MDD d 
= 0.81, between HC and BD d = 1.28) with N = 23 subjects, we calculated a power of 0.73 
for the comparison between HC versus MDE (0.34 for the comparison HC versus MDD, 
0.64 for the comparison HC versus BD) at a significance level of 0.05 using t-test for 
independent samples. We asked what minimum difference between HC and MDE groups 
would have been detectable with our N = 23 subjects if we would have had a power of 0.8, 
and calculated a change of d = 1.24. Lastly, we ccomputed the number of participants that 
would be needed to detect a change similar in size of our observed effect (d = 1.13) with a 
power of 0.8, yielding at least N = 21 participants.
4 Discussion
This is the first study to evaluate oxCOX signal using NIRS in subjects experiencing major 
depressive episodes. The oxCOX signal is a proposed marker of mitochondrial health (Bale, 
Elwell, and Tachtsidis 2016). Our results indicate that both experimentally measured oxCOX 
signal and computationally modelled mitochondrial parameters are altered in mood 
disorders. There were two main findings. Firstly, experimentally measured oxCOX activity 
was lower in the MDE groups and correlated with depression severity (Figure 1 & 2). 
Secondly, optimized mitochondrial parameters for oxCOX relating to the electron transport 
chain detected lower activity in MDE, largely in the BD disorder group, when compared 
with HC, with lower activity correlating with depression severity (Figures 1 & 2). These 
parameters are potential mitochondrial contributors to an oxCOX marker. Combining 
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oxCOX measurements derived from NIRS with computational modelling may therefore 
potentially enhance our understanding of which factors drive mitochondrial dysfunction in 
MDEs. Our power analysis indicated that the study was relatively underpowered, so these 
data should therefore be considered pilot results that require replication with a larger sample 
size. Confidence in the findings is thus tempered by the small sample size limiting statistical 
power for subgroup comparisons, such as between MDD and BD. Although the results 
appear to be largely driven by the BD subjects, despite the lack of a significant difference 
between MDD versus BD, we observed differences between MDE and controls and lack of a 
difference between BD and controls. Together, our results suggest that mitochondrial 
abnormalities that have been previously reported in the periphery (L. Holper, Ben-Shachar, 
and Mann 2018) may be present in the brain in mood disorders.
The computational model used here cannot prove dysfunction of the modelled mitochondrial 
mechanisms, because the optimized parameters are estimates and not true physical 
quantities. The model can, however, approximate alterations in the mitochondrial 
mechanisms that in principle can produce the reduced oxCOX response observed in 
depressed patients (Caldwell, Hapuarachchi, et al. 2015). These mechanisms may reflect 
disease-specific information that may together be used as a marker of mitochondrial health 
in MDEs. We briefly highlight the main functions of the parameters analysed here, and 
discuss their relevance to current literature in mood disorders.
COX (also known as complex IV) is the last enzyme of the ETC within the process of 
oxidative phosphorylation at the inner mitochondrial membrane. CuA,o,n represents the 
normal concentration of its oxidized CuA center (i.e., after the loss of electrons), indicating 
the portion of COX already used for electron transfer, in contrast to the concentration of 
reduced CuA (CuA,r,n, i.e., after the gain of electrons), whereas COXtis indicates its overall 
concentration in tissue. In the case of COX deficiency as part of the pathophysiology of 
depression, both CuA,o,n and COXtis would be expected to decrease because of less 
functional COX availability, as observed in the present study (Figure 1). The correlation with 
depression severity corroborates our results suggesting that CuA,o,n and COXtis can be 
related to physical quantities (Figure 2).
The NAD+/NADH ratio (nicotinamide adenine dinucleotide, NAD) is the product of 
complex I (NADH dehydrogenase) of the ETC. The two enzymes, complexes I and IV, are 
functionally closely related in that complex IV is required for the assembly and stability of 
complex I (Li et al. 2007; Diaz et al. 2006; Schäfer et al. 2007). Although, our model does 
not directly estimate complex I activity, we can use its product, the NAD+/NADH ratio, as 
an indicator of complex I functioning. The NAD+/NADH ratio defines the balance between 
oxidized NAD+ biosynthetic and reduced NADH consuming pathways, which plays a 
critical role in energy production and antioxidant defences. Due to its proton pumping 
function at the beginning of the ETC (Schäfer et al. 2007; Rich 2003; Belenky, Bogan, and 
Brenner 2007), the NAD+/NADH ratio can be thought of as the fuel of the ETC (Belenky, 
Bogan, and Brenner 2007; Houtkooper et al. 2010; Lin and Guarente 2003). A decrease of 
the NAD+/NADH ratio can lead to the formation of reactive oxygen species that potentially 
contribute to mitochondrial damage (Lin and Guarente 2003; Murphy 2009; Ben-Shachar 
and Karry 2008). In the case of deficient COX as part of the pathophysiology of depression, 
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the NAD+/NADH ratio would be expected to decrease, as observed in the present study 
(Figure 1). The correlation of the NAD+/NADH ratio with depression severity indicates that 
the scenario modelled here, could be related to physical quantities (Figure 2).
The potential importance of the interplay between NADH-dehydrogenase (complex I) and 
COX (complex IV) (Li et al. 2007) in depression is also supported by previous studies 
reporting less complex I and IV activity in MDD (Gardner et al. 2003, 2008; Ben-Shachar 
and Karry 2008) and BD (Washizuka et al. 2005; X. Sun et al. 2006; de Sousa et al. 2015; 
Beech et al. 2010; H. K.Kim et al. 2016; Konradi C et al. 2004; Altar et al. 2005; Ben-
Shachar and Karry 2008; Iwamoto, Bundo, and Kato 2005; Naydenov AV et al. 2007), a 
reduced complex I/IV enzyme-ratio in muscle mitochondria of MDD patients (Gardner et al. 
2003) as well as a reduction of the NAD+/NADH ratio in patients with first-episode BD as 
assessed using MRS (S.-Y. Kim et al. 2017). 1
The fundamental proton pumping role of both complexes I and IV (Barney 2017) builds and 
maintains the transmembrane proton gradient used by ATP synthase to synthesize most of 
the cell’s ATP (Wikstrom 1977). The proton-motive force, Δp, resulting from that 
transmembrane proton gradient, promotes proton movement down the electrochemical 
potential across the mitochondrial membranes in two directions. The protons pumped out of 
the mitochondria are used by COX for electron transfer, and thus, reduction of O2 to H2O. 
Protons re-enter the mitochondria via two processes, either associated with ATP production 
or through endogenous proton leak channels (Nicholls 1977; Korzeniewski and Zoladz 
2001). These proton leaks serve the important purpose of preventing dielectric membrane 
breakdown (in limiting Δp), and restricting leakage of single electrons from the ETC to form 
superoxide (Brand et al. 1994; Rolfe and Brand 1997). The parameters klk2 (the parameter 
controlling the sensitivity of the leak current to changes in Δp) and ck1 (a parameter 
controlling the sensitivity of k1 to Δp), correlated with depression severity or differed 
between patients and controls (Figures 1 & 2). Hence, a major endpoint of all of these 
processes is the maintenance of Δp, as it is key to mitochondrial survival (Storey 2004). 
Under conditions of deficient COX activity with insufficient proton pumping, the resultant 
collapse of Δp can lead to cells becoming ATP users instead of being ATP producers 
(Wikström et al. 2015). This ATP imbalance may be related to some of the 
pathophysiological manifestations of mood disorders such as fatigue, lack of motivation or 
working memory deficits (E. Streck et al. 2014; Karabatsiakis et al. 2014).
The current literature provides several hypotheses on the connection between mitochondrial 
dysfunction an mood disorders (McCann and Ross 2018), based on glucocorticoid-induced 
stress (Wallace 2005), oxidative stress (Bakunina, Pariante, and Zunszain 2015), and 
susceptibility to genetic alterations (Pei and Wallace 2018). The assumption that COX 
activity might be more deficient in BD compared with MDD, as our findings might suggest 
(Fig. 1–2), needs to be replicated in a future study. A study in a larger and medication-free 
sample of MDD and BD subjects would address this question. It also remains to be 
1Notably, while MRS measures total, free and protein-bound NAD+ and NADH forms because spectroscopy cannot distinguish 
between subcellular (i.e., cytosolic or mitochondrial) compartments (Lu et al. 2014; Du F et al. 2014), the current BS model version 
(Caldwell, Hapuarachchi, et al. 2015) calculates mitochondrial NAD+ and NADH concentrations.
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determined in BD whether this deficient COX activity is absent when the patient becomes 
euthymic and how it is impacted by a switch into mania.
Several methodological limitations should be considered when interpreting our findings. The 
sample size was small and the MDE groups were heterogenous with respect to diagnosis, 
age, and medication status. The majority (6/7) of the MDD patients were older than 60 years 
of age and met criteria for late-life depression (LLD). LLD differs from younger patients 
with MDD in both pathophysiology and clinical presentation (Glover and Srinivasan 2013). 
Since there is an age-dependent decline of mitochondrial functioning (N. Sun, Youle, and 
Finkel 2016; L. Holper, Ben-Shachar, and Mann 2018), the present results may not 
generalize to a younger MDD population. However, our findings of lower activity in MDE 
survived statistical age-adjustment and we therefore suggest that age may not be the main 
contributing factor for the observed reduced COX activity in MDE. The lack of effect of age 
on differences between MDE and HC groups may be explained by the fact that the group 
differences were largely driven by the BD group, and that BD did not have significant age 
differences from HCs. Of note, most of the patients were medicated. One of the MDD 
subjects was taking escitalopram, a selective serotonin reuptake inhibitor (SSRI). We note 
that this patient’s data were not outliers in the analysis. Escitalopram has not been shown to 
affect mitochondrial function in general or COX activity in particular (Gonçalves et al. 2012; 
Shetty et al. 2015), although other SSRIs may decrease mitochondrial function (Adzic et al. 
2016; Hroudová and Fisar 2010). Further, 5/6 of BD patients had commenced antidepressant 
treatment with fluoxetine, another SSRI, within two weeks of scanning. Fluoxetine has so 
far not been reported to have a clear effect on COX but that may depend on sex (Adzic et al. 
2013; Adzic, Mitic, and Radojcic 2017) and be brain region-specific (Shumake et al. 2010; 
Freo et al. 2000; Padilla et al. 2011). Lastly, all BD patients were receiving mood stabilizers 
at the time of scanning. Mood stabilizers, such as lithium or valproic acid, when given as 
long-term treatment have not been found to affect mitochondrial function (Kato 2017; Clay, 
Sillivan, and Konradi 2011), instead, they have been suggested to protect against 
mitochondria-targeted neurotoxicity (Bachmann et al. 2009) thereby preserving or even 
enhancing mitochondrial function in general (X. Sun et al. 2006) and COX activity in 
particular (Hroudová and Fisar 2010; Bachmann et al. 2009; E. L. Streck et al. 2015; 
Cancelier et al. 2017). Our results showed that these medications may had modest effects on 
oxCOX or related parameters (Table 3). Based on the literature and these findings, it is 
unlikely that the larger effects in BD are solely driven by an inhibition of COX by the small 
effects of SSRIs; nevertheless, our findings require further evaluation in medication-free 
depressed patients.
In conclusion, we found in this pilot study that the brain oxCOX signal was lower in MDE, 
and computational modelling identified alterations in key parameters of mitochondrial 
metabolism based on the impaired oxCOX signal. While this preliminary finding is 
consistent with measures of mitochondrial function in blood cells and muscle biopsies, and 
reports of less FDG uptake in dorsolateral prefrontal cortex in MDE, we cannot rule out an 
effect of antidepressants, or be certain that the finding is present in both MDD and BD. The 
small number of subjects as well as the intergroup heterogeneity is not sufficient for a robust 
conclusion. Future research therefore needs to replicate our findings in a larger, unmedicated 
mood disorder sample. Given the reported implication of mitochondrial abnormalities in BD 
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and other psychiatric illnesses reported in blood, muscle and now here in brain, the study of 
mitochondrial metabolism using NIRS is an exciting, novel approach to disease etiology. Its 
correlation with depression severity suggests that oxCOX may be a potential biomarker of 
clinical response, and perhaps even a novel target of treatment.
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Figure 1. Signal and parameter changes.
Boxplots illustrating the oxCOX and TOI signal changes and the parameters optimized for 
the oxCOX signals being significantly different between patients and controls as assessed 
using ANOVA. Note that the parameters values, and thus the percentage changes (%), are 
estimates and not true physical quantities. Note that the oxCOX and TOI signals on top 
assume an arbitrary 50% change in controls. Parameters are defined in Table 2 and statistics 
are reported in Table 3.
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Figure 2. Correlation oxCOX parameters and HDRS.
Scatter plots of the correlation between depression severity and selected parameters 
optimized for the oxCOX signal assessed using Spearman correlation, i.e., CuA,o,n (r = 
−0.72, p = 0.006), klk2 (r = −0.63, p = 0.022) and COXtis (r = −0.58, p = 0.039). These 
parameters correlated inversely with increasing depression severity indicating lower 
oxidative properties with higher symptom severity. Note that the parameters values, and thus 
the percentage changes (%), are estimates and not true physical quantities. Parameters are 
defined in Table 2 and statistics are reported in Table 3.
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Table 1.
Demographics.
Patients with major depression disorder (MDD, N = 7) and bipolar disorder (BD, N = 6) compared to controls 
(N = 10). m = male, f = female. HDRS = Hamilton Depression Rating Scale. Medication: escitalopram 
(20mg/d), fluoxetine (20mg/d), lamotrigine (250mg/d), lithium (1350mg/d), valproic acid (750–1000mg/d).






MDD f 30 1 0 none More than one race 17
MDD f 63 39 3 none Black or African American 21
MDD f 63 23 1 none Black or African American 16
MDD f 63 31 1 none Black or African American 13
MDD f 79 19 1 escitalopram White 18
MDD f 70 26 1 none White 17
MDD m 83 18 0 none White 12
BD f 44 21 0 valproic acid, fluoxetine White 16
BD f 29 23 0 lamotrigine, fluoxetine White 15
BD m 56 19 0 lithium White 16
BD m 45 23 1 valproic acid, fluoxetine Black or African American 17
BD f 23 29 3 valproic acid, fluoxetine White 16
BD m 48 26 0 valproic acid, fluoxetine White 17
Control m 52 0 0 none Black or African American 13
Control f 28 5 0 none White 14
Control m 41 0 0 none White 16
Control f 26 1 0 none Black or African American 19
Control m 23 3 0 none Asian 17
Control f 24 6 0 none White 16
Control f 31 1 0 none Black or African American 16
Control f 28 5 0 none White -
Control f 45 0 0 none White 16
Control f 25 3 0 none Black or African American 16
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Table 2.
Optimized model parameters.
The 20 most influential model parameters on oxCOX and TOI included in the optimization are shown with 
initial values and ranges before optimization. Parameters are ordered from top to bottom according to their 
sensitivity to oxCOX and TOI, respectively.
oxCOX parameters Unit Initial
value
Range
oxCOX signal Oxidized cytochrome-c-oxidase assessed by NIRS
CuA,o,n Normal concentration of oxidized CuA mM 0.066 0.046–0.085
Volmit Fraction of brain tissue volume that is mitochondria - 0.067 0.054–0.080
klk2 Constant controlling depending of leak rate Llkon Δp mV−1 0.038 0.030–0.456
Δpn Normal value of Δp (proton-motive force) mV−1 168.611 118.028–219.194
NADn/NADHn Normal NAD+/NADH ratio - 9 0.1–20
k1,n Forward reaction rate for CuAreduction at normal Δp/NADH s−1 8.3 5.810–10.790
ck1 Parameter controlling sensitivity of k1to Δp mV−1 0.01 0.008–0.012
Tmax,0 Maximal muscular tension under normal regulatory stimulus mmHg cm 2.11 1.477–2.743
vCO2,n Normal filtered carbon dioxide partial pressure mmHg 40 28–52
ϕ Oxygen concentration at half-maximal saturation mM 0.036 0.029–0.043
rm Vessel radius at which muscular tension is maximal cm 0.027 0.022–0.032
kunc Parameter simulating effect of uncouplers to the system - 1 0.8–1.2
COXtis Concentration of COX in tissue mM 0.006 0.004–0.007
Llk0 Constant controlling the depending of the leak rate Llk on Δp mM s−1 0.004 0.003–0.006
ptot Total protons moved out of mitochondrial matrix - 20 18–20
Kσ Parameter controlling sensitivity of σe to vessel radius - 10 7–13
CVinh Control parameter representing action of CCO inhibitors - 1 0.8–1.2
vu,n Normal filtered demand - 1 0.7–1.3
h0 Thickness of blood vessel walls at which radius is r0 cm 0.003 0.002–0.004
Pic Intracranial pressure mmHg 9.5 7–11
TOI parameters Unit Initial
value
Range
TOI signal Tissue oxygenation index assessed by NIRS
Tmax,0 Maximal muscular tension under normal regulatory stimulus mmHg cm 2.109 1.477–2.743
D02 Diffusion rate for oxygen between capillaries and mitochondria s−1 0.842 0.589–1.094
rt Radius in the muscular tension relationship cm 0.018 0.014–0.022
ϕ Oxygen concentration at half-maximal saturation mM 0.036 0.029–0.043
vCO2,n Normal filtered carbon dioxide partial pressure mmHg 40 28–52
rn Normal effective blood vessel radius cm 0.019 0.015–0.022
Kσ Parameter controlling sensitivity of σe to vessel radius - 10 7–13
Volv Relative venous blood volume - 0.75 0.525–0.975
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oxCOX parameters Unit Initial
value
Range
klk2 Constant controlling depending of leak rate Llkon Δp mV−1 0.038 0.030–0.456
vO2,n Normal filtered capillary oxygen concentration mM 0.064 0.045–0.084
kaut Overall functioning of autoregulatory response - 1 0–1
NADn/NADHn Normal NAD+/NADH ratio - 9 0.1–20
vu,n Normal filtered demand - 1 0.7–1.3
σe,0 Parameter in elastic tension relationship mmHg 0.143 0.114–0.171
RCO2 Autoregulatory reactivity to carbon dioxide - 2.2 1.5–2.9
ε0NADH Standard redox potential for NADH mV −320 −384−-256
Δpn Normal value of Δp (proton-motive force) mV−1 168.611 118.028–219.194
COXtis Concentration of COX in tissue mM 0.006 0.004–0.007
Llk0 Constant controlling depending of leak rate Llk on Δp mM s−1 0.004 0.003–0.006
p2 Proton cost of reaction reducing a3 − 4 2.8–5.2
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Table 3.
ANOVA for oxCOX and TOI and their related parameters. Main effects are shown between diagnoses within 
depressive episodes (MDE) versus controls, with post-hoc comparisons between major depressive disorder 
(MDD) and bipolar disorder (BD) versus controls; there were no significant differences between MDD and 
BD. A separate ANOVA tested medication effects for which main effects are shown between subjects 
receiving medication versus no medication, with post-hoc comparisons between mood stabilizers (MS) and 
antidepressants (AD) versus no medication (none). The covariate age had no significant effect. (Last two 
columns) Spearman correlation for oxCOX and TOI and their related parameters across MDD and BD 
patients with HDRS. Significant effects are highlighted (bold). Definitions of parameters can be found in Table 
2.
ANOVA diagnoses ANOVA medication Correlation














F2,20 p-value p-value p-value F2,20 p-value p-value p-value r p-value
oxCOX signal 7.22 0.014 1.000 0.028 2.35 0.121 1.000 1.000 −0.72 0.006
CuA,o,n 9.86 0.005 0.435 0.012 1.36 0.280 1.000 1.000 −0.22 0.473
Volmit 1.66 0.212 0.678 0.459 0.98 0.391 0.352 0.508 0.42 0.155
klk2 8.72 0.008 0.760 0.017 1.62 0.224 1.000 0.685 −0.63 0.022
Δpn 0.57 0.457 1.000 1.000 0.70 0.509 1.000 1.000 −0.30 0.325
NADn/NADHn 14.18 0.001 0.627 0.002 3.68 0.044 1.000 0.732 −0.19 0.526
k1,n 3.47 0.076 1.000 0.156 3.34 0.056 0.137 0.054 −0.45 0.121
ck1 5.09 0.035 1.000 0.055 3.17 0.064 1.000 0.586 −0.23 0.444
Tmax,0 1.12 0.302 0.265 0.774 3.47 0.051 1.000 0.364 0.13 0.665
vCO2,n 0.09 0.771 1.000 1.000 0.88 0.429 0.398 0.554 0.11 0.719
ϕ 6.03 0.023 1.000 0.107 3.75 0.041 0.708 1.000 −0.01 0.971
rm 0.15 0.702 0.264 1.000 1.80 0.191 0.485 1.000 −0.35 0.246
kunc 0.64 0.434 0.688 0.838 0.37 0.697 0.854 1.000 −0.31 0.302
COXtis 3.96 0.060 1.000 0.101 2.43 0.113 1.000 0.243 −0.58 0.039
Llk0 0.69 0.417 0.352 0.895 1.06 0.364 0.496 1.000 −0.02 0.957
ptot 0.82 0.375 1.000 0.718 1.81 0.189 0.540 1.000 0.49 0.089
Kσ 0.01 0.907 1.000 1.000 0.52 0.604 0.677 0.687 0.12 0.692
CVinh 0.14 0.712 0.871 1.000 0.20 0.818 1.000 1.000 0.09 0.766
vu,n 1.28 0.271 1.000 0.563 1.82 0.188 0.283 1.000 −0.32 0.280
h0 0.00 0.986 1.000 1.000 0.23 0.799 1.000 1.000 0.23 0.444
Pic 2.04 0.168 0.614 0.369 0.52 0.605 0.803 1.000 −0.16 0.606
TOI signal 0.50 0.487 1.000 0.996 1.50 0.248 0.213 0.472 −0.27 0.369
Tmax,0 2.32 0.143 1.000 0.430 1.99 0.163 1.000 0.960 −0.29 0.331
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ANOVA diagnoses ANOVA medication Correlation














F2,20 p-value p-value p-value F2,20 p-value p-value p-value r p-value
D02 0.15 0.699 1.000 1.000 0.37 0.694 0.816 1.000 −0.04 0.901
rt 0.31 0.582 1.000 1.000 2.49 0.108 0.108 0.460 0.16 0.613
ϕ 0.06 0.811 1.000 1.000 0.20 0.824 1.000 1.000 0.18 0.681
vCO2,n 1.10 0.306 0.406 0.661 0.04 0.960 1.000 1.000 0.25 0.403
rn 2.53 0.126 0.756 0.181 3.08 0.068 1.000 0.216 −0.13 0.667
Kσ 5.71 0.026 1.000 0.074 2.06 0.154 1.000 1.000 −0.28 0.349
Volv 2.29 0.145 1.000 0.519 1.62 0.222 1.000 1.000 −0.09 0.779
klk2 2.20 0.153 0.703 0.287 1.46 0.257 0.316 0.857 0.04 0.685
vO2,n 0.07 0.791 0.777 1.000 0.31 0.739 1.000 0.885 0.24 0.424
kaut 1.00 0.329 0.205 0.515 0.12 0.891 1.000 1.000 −0.29 0.334
NADn/NADHn 0.52 0.480 1.000 0.943 3.11 0.067 0.091 0.578 −0.29 0.336
vu,n 0.44 0.513 0.669 0.916 1.29 0.297 1.000 0.493 0.34 0.255
σe,0 0.55 0.468 0.978 0.861 0.98 0.391 1.000 0.739 0.31 0.305
RCO2 0.08 0.780 0.445 1.000 1.17 0.330 0.967 0.393 0.30 0.318
ε0NADH 0.00 0.987 1.000 1.000 0.77 0.478 0.652 1.000 0.20 0.508
Δpn 0.02 0.876 0.925 1.000 0.49 0.619 1.000 0.701 0.49 0.086
COXtis 0.04 0.846 1.000 1.000 0.65 0.534 0.538 0.701 −0.11 0.729
Llk0 0.30 0.592 0.828 1.000 0.89 0.427 1.000 0.655 0.41 0.163
p2 3.00 0.098 1.000 0.163 3.19 0.063 0.177 0.045 0.40 0.173
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